- Home
- RIGL vs SLDP Comparison
RIGL vs SLDP Comparison
Compare RIGL & SLDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- SLDP
- Stock Information
- Founded
- RIGL 1996
- SLDP 2011
- Country
- RIGL United States
- SLDP United States
- Employees
- RIGL N/A
- SLDP N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- SLDP Electrical Products
- Sector
- RIGL Health Care
- SLDP Energy
- Exchange
- RIGL Nasdaq
- SLDP Nasdaq
- Market Cap
- RIGL 247.1M
- SLDP 230.9M
- IPO Year
- RIGL 2000
- SLDP N/A
- Fundamental
- Price
- RIGL $22.07
- SLDP $1.14
- Analyst Decision
- RIGL Buy
- SLDP Buy
- Analyst Count
- RIGL 4
- SLDP 4
- Target Price
- RIGL $31.13
- SLDP $3.00
- AVG Volume (30 Days)
- RIGL 151.9K
- SLDP 1.3M
- Earning Date
- RIGL 11-07-2024
- SLDP 11-07-2024
- Dividend Yield
- RIGL N/A
- SLDP N/A
- EPS Growth
- RIGL N/A
- SLDP N/A
- EPS
- RIGL 0.22
- SLDP N/A
- Revenue
- RIGL $156,374,000.00
- SLDP $18,026,000.00
- Revenue This Year
- RIGL $38.26
- SLDP $15.90
- Revenue Next Year
- RIGL $24.21
- SLDP $117.35
- P/E Ratio
- RIGL $99.67
- SLDP N/A
- Revenue Growth
- RIGL 19.95
- SLDP N/A
- 52 Week Low
- RIGL $7.48
- SLDP $1.08
- 52 Week High
- RIGL $22.85
- SLDP $2.35
- Technical
- Relative Strength Index (RSI)
- RIGL 83.76
- SLDP 33.00
- Support Level
- RIGL $13.91
- SLDP $1.12
- Resistance Level
- RIGL $14.70
- SLDP $1.28
- Average True Range (ATR)
- RIGL 1.04
- SLDP 0.05
- MACD
- RIGL 0.50
- SLDP -0.01
- Stochastic Oscillator
- RIGL 91.59
- SLDP 0.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About SLDP Solid Power Inc.
Solid Power Inc is engaged in developing all-solid-state battery cell technology to enable the next generation of batteries for the EV and other markets. The company's planned business model is to license its all-solid-state battery cell designs and manufacturing know-how to top tier battery manufacturers or automotive original equipment manufacturers and to sell its sulfide-based solid electrolyte for incorporation into all-solid-state battery cells.